Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation - Wikidata - awgldk - TriplyDB

Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation

Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation

http://www.wikidata.org/entity/Q37100147

about

Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome?Cardiac matrix: a clue for future therapy Changes in matrix metalloproteinase-9 levels during progression of atrial fibrillation Gene therapy from the perspective of systems biology.Pharmacotherapy for end-stage coronary artery disease.MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure.Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome.Glycemic control influences serum angiogenin concentrations in patients with type 2 diabetes miR-21 normalizes vascular smooth muscle proliferation and improves coronary collateral growth in metabolic syndrome Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia Effects of diabetes mellitus on VEGF-induced proliferation response in bone marrow derived endothelial progenitor cells Mitochondrial division/mitophagy inhibitor (Mdivi) ameliorates pressure overload induced heart failure Effects of neuropeptide Y on collateral development in a swine model of chronic myocardial ischemia Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure Folic acid mitigates angiotensin-II-induced blood pressure and renal remodeling.Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.Acute myocardial rescue with endogenous endothelial progenitor cell therapy.Overfed Ossabaw swine with early stage metabolic syndrome have normal coronary collateral development in response to chronic ischemia.Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.Resveratrol preserves myocardial function and perfusion in remote nonischemic myocardium in a swine model of metabolic syndrome.Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy.Changes of serum angiogenic factors concentrations in patients with diabetes and unstable angina pectoris Myocardial therapeutic angiogenesis: a review of the state of development and future obstacles Exercise training and peripheral arterial disease.TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure Exercise increases serum endostatin levels in female and male patients with diabetes and controls.Anti-Parstatin Promotes Angiogenesis and Ameliorates Left Ventricular Dysfunction during Pressure Overload.Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion.Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors.Endostatin is protective against monocrotaline-induced right heart disease through the inhibition of T-type Ca(2+) channel.Negative regulators of angiogenesis: important targets for treatment of exudative AMD.Physical inactivity increases endostatin and osteopontin in patients with coronary artery disease.Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology.Association of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burden.Impaired coronary collateral growth in the metabolic syndrome is in part mediated by matrix metalloproteinase 12-dependent production of endostatin and angiostatin.Less fibrosis in elderly subjects supplemented with selenium and coenzyme Q10-A mechanism behind reduced cardiovascular mortality?Endostatin: a promising biomarker in the cardiovascular continuum?Cardiac stem cell trials and the new world of cellular reprogramming: Time to move on.Clinical parameters associated with collateral development in patients with chronic total coronary occlusion.HIF-Prolyl Hydroxylase 2 Inhibition Enhances the Efficiency of Mesenchymal Stem Cell-Based Therapies for the Treatment of Critical Limb Ischemia

P2860

Q27015707-B7EF6C62-9830-433C-B91E-19096DF3B5DC Q27026864-A249DCDD-30DE-4581-B9D7-B998092E11ED Q28304239-21D8D640-4BA6-4439-B674-7576BD5D1C1F Q30430438-5C7F58E9-FE95-4588-B036-0BF1E60BFCFA Q33610142-D7CDA59D-2D18-47CB-9969-A7AB301F00BC Q33887793-99333E80-C88F-4635-B45D-101A568036A4 Q34009401-CF9F8D44-C3DF-430B-A32B-86621504F854 Q34016097-DB939D6C-ACD1-4161-86B5-16BC98DE2CE0 Q34072676-5F75FFDA-C264-44A6-ABBE-857293185028 Q34147482-DC21B300-447B-4A96-A0F8-2D00493054CE Q34217568-6ABDC3B5-B681-46C8-A08D-7A9F075E03E5 Q34221157-E6A68A64-93E5-4E67-A336-FDA2C4478FBC Q34288422-07C88F14-2A62-412C-AA25-FA890E005CD5 Q34785035-01E7DBA0-040D-4C49-A9B0-C70DFAA77928 Q35080666-7F1AA6E2-F154-4CC3-A44E-78F13FBB344A Q35140747-49FD5711-4E3A-4691-B4E7-10A5693D3848 Q35607069-A2E67BAD-FE6F-425E-AF79-FFB03FC5A6ED Q36143074-04151C8E-9611-44C9-BB3D-D666BB0DC66D Q36220259-53F42381-C62B-48A4-9E00-84BA1E4BD86D Q36339075-016BE9E1-F99E-4F8B-9597-4050F8AF16CE Q36350701-0533C94E-4AAF-486A-89DE-30C52260CC8D Q36687489-F16AE196-AEB1-421F-AE0D-0BAB23F168B8 Q36820684-2645DFA2-0196-49CC-A465-3CA1AC2516EF Q37157213-F22CF864-210C-4500-9930-A3F9F5364369 Q37435828-043CA5A4-F83F-4D4C-B5C3-49FB4F91047A Q37554657-38FF3317-D34F-4FD4-B42D-AAFCAC774F5C Q37685882-0BFEDB77-8E42-4FC9-87D4-EC9179490431 Q37726706-B195E21C-5311-4971-82B5-9AFD9CEE22EB Q38081027-83E50FAA-37D6-4F46-925A-7C781A8EC291 Q38782650-DEF2ED41-4C93-437C-94C9-1491C496AD94 Q39416208-03122067-C9BC-42B6-B20C-18D0B14899ED Q40218169-32D718FB-04D0-406C-95CC-BDFAD8697B92 Q41771942-69A180E5-9245-47DE-BCC8-FF663F3580E2 Q42287888-75163340-A190-44E0-875D-534B62C9C699 Q42571891-E66AB6D3-E30F-4AB6-858C-6A23CFAB97AF Q47582008-C879EB6B-101D-4A37-9500-7D9E9D688BB7 Q47667458-04291D12-2A52-437E-8958-1DF7F6ED408D Q49353094-F1EBCB22-B597-42F0-8A8E-BD47EC121696 Q51211403-BBF6AAA8-9416-4AE5-836E-FF945F505174 Q57767255-F0E32562-761C-4CFF-A42B-8F61B0556ED5

P2860

Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation

http://www.wikidata.org/entity/Q37100147

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Endostatin and angiostatin are ...... coronary collateral formation

@en

Endostatin and angiostatin are ...... coronary collateral formation.

@nl

type

label

Endostatin and angiostatin are ...... coronary collateral formation

@en

Endostatin and angiostatin are ...... coronary collateral formation.

@nl

prefLabel

Endostatin and angiostatin are ...... coronary collateral formation

@en

Endostatin and angiostatin are ...... coronary collateral formation.

@nl

P1433

Q37100147-3A565EB8-EE33-44E0-BFD7-17A998C89888

P1476

Q37100147-43D33298-4FB9-418B-B622-77F595323456

P2093

Q37100147-2B6ACFAD-B6B1-47FE-86AA-D3695B1D20F9

Q37100147-2D3C7024-72FC-4EA2-8816-F591C256BC27

Q37100147-74555C69-F192-4A0F-A71D-76232D73BFE7

Q37100147-7A525F04-4125-4D3C-BFEF-36DB7324A96F

Q37100147-8BACF4AE-BA1F-4248-80A5-B944AB95E3AE

Q37100147-C5043074-1AE7-4CA8-B959-91C70F3A6BF1

Q37100147-ED0E9A05-81DD-4AB8-929F-CA38873500BC

P2860

Q37100147-089A3FD8-D42D-4131-9036-4C23F888434B

Q37100147-0FF2C5E2-4F6B-4DF1-AE86-1155790FEA03

Q37100147-11DDDC51-BC11-4672-8BE2-A79D39A57A07

Q37100147-1E4D88DA-C379-4826-90BC-737CC198DBCD

Q37100147-27A02B1E-FB22-48B0-9E9D-37522609C275

Q37100147-2D5C22CC-85A5-48FC-9E06-0D5763AACD9C

Q37100147-423E0A56-5499-4144-83E5-4F5C297178E0

Q37100147-43021F93-8694-4617-ACCC-DCBABC2FD5CE

Q37100147-4791D0C6-1307-415C-8D03-ACBB675305E0

Q37100147-656E751B-5BA4-4315-8654-E8310920DB9D

P304

Q37100147-79B75A3B-C596-4CAB-B35F-B5223A93F4E5

P31

Q37100147-02BC3A17-C105-4375-AEB9-EBDB6CEEFCFE

P356

Q37100147-B9513A87-F872-49EE-AB3F-E6DA8FB6D615

P433

Q37100147-2777EE27-E388-4D50-A4A1-E5BCFDF142F6

P478

Q37100147-5561C277-6727-439C-B81E-4FDDE7717B56

P577

Q37100147-3798E699-1468-468B-A868-41D906C6569A

P5875

Q37100147-F8B7ADC5-D4AD-4751-B0A1-400EE8821B16

P698

Q37100147-A7304362-61FA-4283-9BCE-A233B91453A8

P921

Q37100147-0760A21C-8B78-4630-ACC6-401151D843D3

P932

Q37100147-3FA7AFAE-CCD2-4E90-AA3C-F6C9CC2B8D27

P356

AJPHEART.00283.2008

P1433

American Journal of Physiology - Heart and Circulatory Physiology

P1476

Endostatin and angiostatin are ...... coronary collateral formation

@en

P2093

Cesario Bianchi

http://www.w3.org/2001/XMLSchema#string

Frank W Sellke

http://www.w3.org/2001/XMLSchema#string

Munir Boodhwani

http://www.w3.org/2001/XMLSchema#string

Neel R Sodha

http://www.w3.org/2001/XMLSchema#string

Richard T Clements

http://www.w3.org/2001/XMLSchema#string

Roger J Laham

http://www.w3.org/2001/XMLSchema#string

Shu-Hua Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Angiostatin binds ATP synthase on the surface of human endothelial cells

Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

Interaction of endostatin with integrins implicated in angiogenesis

Secreted cathepsin L generates endostatin from collagen XVIII

Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin

Tumor angiogenesis: therapeutic implications

Tissue inhibitors of metalloproteinases: evolution, structure and function

Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase

Role of angiogenesis in tumor growth and metastasis

P304

H428-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPHEART.00283.2008

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

296

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23655574

http://www.w3.org/2001/XMLSchema#string

P698

19074676

http://www.w3.org/2001/XMLSchema#string

P921

P932

2643884

http://www.w3.org/2001/XMLSchema#string